Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | Chief Financial Officer | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 684,970 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 202,000 · Balance 684,970 F1: On February 26, 2026, the reporting person was awarded 202,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2026, the reporting person was awarded 202,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 21:31 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 202,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-001101 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 684,970 F1 · shares: On February 26, 2026, the reporting person was awarded 202,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 21:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 49,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-000366 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,970 F1 · shares: On March 17, 2025, the reporting person was awarded 164,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 49,200 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 16,400 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 114,800 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 26,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-006103 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,770 F1 · shares: On August 15, 2025, the reporting person was awarded 26,143 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 13,072 units and 13,071 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-005251 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,627 F1 · shares: The reporting person received 100,000 restricted stock units under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $2.50 per share of the Issuer's common stock for a minimum of thirty consecutive trading days prior to July 24, 2028, which date shall be no earlier than July 24, 2026, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 17,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-004367 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,627 F1 · shares: On June 1, 2025, the reporting person was awarded 17,406 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 5,802 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 13,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-001455 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,221 F1 · shares: On March 1, 2025, the reporting person was awarded 13,969 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,657 units, 4,656 units, and 4,656 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 12,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-007801 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,252 F1 · shares: On December 1, 2024, the reporting person was awarded 12,683 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,228 units, 4,228 units, and 4,227 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 13,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005498 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,569 F1 · shares: On September 1, 2024, the reporting person was awarded 13,493 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,498 units, 4,498 units, and 4,497 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005022 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,076 F1 · shares: On Sept 28, 2023, the reporting person was awarded 78,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 19,500 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 6,500 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 33,150 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 25,350 RSUs did not vest and were cancelled on August 15, 2024. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 11,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003481 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,576 F1 · shares: On June 1, 2024, the reporting person was awarded 11,686 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,896 units, 3,895 units, and 3,895 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-000404 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,890 F1 · shares: On September 28, 2023, the reporting person was awarded 78,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 33,150 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 11,050 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-007775 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,740 F1 · shares: On October 19, 2023, the reporting person was awarded 100,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of thirty consecutive trading days prior to October 19, 2026, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:03 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 24,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005120 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,740 F1 · shares: On October 4, 2022, the reporting person was awarded 55,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,750 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 8,250 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 9,625 RSUs and 20,625 RSUs subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:03 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 20,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000276 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,990 F1 · shares: On October 4, 2022, the reporting person was awarded 55,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 20,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 6,875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 9,625 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:08 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 9,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007703 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,365 F1 · shares: On October 4, 2022, the reporting person was awarded 55,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 9,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three installments of 3,209 units, 3,208 units, and 3,208 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007485 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,740 F1 · shares: On October 4, 2022, the reporting person was awarded 100,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of ten consecutive trading days prior to October 4, 2025, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 36,821 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-004652 · form4.xml · derivative · entry 2 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,647 Underlying: Common Stock · 36,821 shares Expires 2031-08-03 F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 56,647 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 36,821 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 18,411 shares and 18,410 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 19,826 shares subject to the award previously vested and remain subject to time-based vesting. F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 56,647 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 36,821 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 18,411 shares and 18,410 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 19,826 shares subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 19,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004652 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,740 F1 · shares: On August 3, 2021, the reporting person was awarded 30,740 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 19,981 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 9,991 units and 9,990 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 10,759 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 19,826 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-002189 · form4.xml · derivative · entry 2 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,826 Underlying: Common Stock · 19,826 shares Expires 2031-08-03 F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 56,647 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 19,826 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 9,913 shares on each of August 3, 2022 and August 3, 2023, respectively. F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 56,647 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 19,826 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 9,913 shares on each of August 3, 2022 and August 3, 2023, respectively. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 10,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002189 · form4.xml · nonDerivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,759 F1 · shares: On August 3, 2021, the reporting person was awarded 30,740 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 10,759 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 5,379 units and 5,380 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:44 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantWarrant (Right to Buy) · Derivative | 185,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001078782-21-000087 · primary_doc.xml · derivative · entry 1 Hughes Terig · CIK 0001841309 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2027-02-01 F1 · date: On February 1, 2021, the Reporting Person was granted a warrant to purchase up to 185,000 shares of Common Stock of the issuer at an exercise price of $4.90 per share. The warrant will vest in full twelve months from the date of grant (subject to continuous employment through such date). F1 · shares: On February 1, 2021, the Reporting Person was granted a warrant to purchase up to 185,000 shares of Common Stock of the issuer at an exercise price of $4.90 per share. The warrant will vest in full twelve months from the date of grant (subject to continuous employment through such date). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.